GE Healthcare completes acquisition of Whatman plc
GE Healthcare, a unit of General Electric Company announced that it has completed the acquisition of Whatman plc, a global supplier of filtration products and technologies.
The acquisition expands GE Healthcare's offering for life science research and biopharmaceutical manufacturing. GE Healthcare's Life Sciences business is a world-class provider of technologies for cellular and protein science research, and tools used in the manufacture of biopharmaceuticals such as vaccines, cell therapies and antibodies. The addition of Whatman's innovative filters and membranes for laboratory research, life sciences and medical technology applications shall offer substantial customer benefits and create significant synergies through complementary product and service offerings.
Commenting on the close, Peter Ehrenheim President and CEO of GE Healthcare's Life Sciences business said: "Whatman's expertise and reputation in filtration technologies and sample preparation is a great fit for our Life Sciences business. We believe that combining the skills of the two companies will enable GE Healthcare to create strong added value for customers in biomedical and drug discovery research."
Topics
Organizations
Other news from the department business & finance
These products might interest you

Cell culture filtration solutions by Cytiva
Cell culture filtration products
High-performance sterile filtration for media, protein purification, and cell culture

Hahnemühle LifeScience Catalogue Industry & Laboratory by Hahnemühle
Wide variety of Filter Papers for all Laboratory and Industrial Applications
Filtration Solutions in the Life Sciences, Chemical and Pharmaceutical Sectors

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
Genetic key discovered to dramatically increase yields and improve taste of hybrid tomato plants
Novartis Phase III study shows once-daily NVA237 is superior to placebo and similar to tiotropium in improving lung function in COPD - GLOW2 study shows NVA237 provides superior 24-hour bronchodilation to placebo (p
Corcept Therapeutics and Xceleron sign agreement for microdosing study using accelerator mass spectrometry

Unhealthy environment causes cardiovascular disease - Two-thirds of noncommunicable diseases caused by environmental factors
Mullerian_agenesis
Pat Mackin Joins CryoLife Board of Directors
